Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium.
PMID : 28760216 ·
J, o, n, a, t, h, a, n, , H, , S, e, l, t, z, e, r, ;, , T, e, d, , H, e, i, s, e, ;, , P, e, t, e, r, , C, a, r, s, o, n, ;, , D, a, n, i, e, l, , C, a, n, o, s, ;, , J, o, , C, a, r, o, l, , H, i, a, t, t, ;, , P, a, s, c, a, l, , V, r, a, n, c, k, x, ;, , T, h, o, m, a, s, , C, h, r, i, s, t, e, n, ;, , D, o, n, a, l, d, , E, , C, u, t, l, i, p
Publicité
Résumé
This white paper provides a summary of presentations, discussions and conclusions of a Thinktank entitled "The Role of Endpoint Adjudication in Medical Device Clinical Trials". The think tank was cosponsored by the Cardiac Safety Research Committee, MDEpiNet and the US Food and Drug Administration (FDA) and was convened at the FDA's White Oak headquarters on March 11, 2016. Attention was focused on tailoring best practices for evaluation of endpoints in medical device clinical trials, practical
Publicité
Source officielle
Voir sur PubMed →Données issues de PubMed / NCBI. Pour le texte intégral et les informations les plus récentes, consultez toujours la notice officielle.